0 Items
Select Page

Campylobacter

Campylobacter is the most common cause of food poisoning in both the UK and United States, with the great majority of cases occurring from infected poultry.

Our Campylobacter product range includes monoclonal antibodies for both for research applications and immunoassay development.

Campylobacter Background

The bacterial genus Campylobacter are non-spore forming, curved, gram-negative bacteria of the family Campylobacteriacae. Over twenty-five species of Campylobacter have been identified but approximately 90% of human disease is caused by Campylobacter jejuni. Infectious disease caused by pathogenic Campylobacter species is referred to as Campylobacteriosis. Other species of Campylobacter causing Campylobacteriosis include C. coli, C. lari and C. upsaliensis but cases are less frequently reported.

Birds, including poultry, are major reservoirs of C. jejuni, where the bacteria survive in the intestines and crop of healthy birds. Most reported outbreaks of Campylobacteriosis have been associated with the consumption of undercooked poultry or poultry products. Symptoms of infection generally include fever, abdominal cramps, watery or haemorrhagic diarrhoea and weight loss. Although the disease is self-limiting, complications may develop in some cases after infection, which include irritable bowel syndrome, Guillain Barre syndrome and other autoimmune neuropathies (CDC).

Campylobacter Antibodies

Our anti-Campylobacter jejuni monoclonal antibodies are specific for the detection of Campylobacter jejuni species and can be used as a pair in the development of immunoassays.

Our antibodies do not cross react with Helicobacter pylori, Escherichia coli, Salmonella enteriditis, Salmonella paratyphi, Salmonella typhi, Salmonella typhimurium, Shigella boydii, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Yersinia enterocolitica, Listeria monocytogenes or Staphylococcus aureus.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Using Adenoviruses to Fight Cancer

In the second of a 2-part series, we discuss how adenoviruses are being developed to treat cancer and some of the hurdles these platforms face from our own immune systems. Curing cancer is one of the biggest challenges of the 21st century. Our knowledge of cancer’s...

New Immunofluorescence Data for our CMV, Yellow Fever and Ebola Antibodies

In September 2018 The Native Antigen Company and Virology Research Services (VRS) were awarded the Medical Research Council (Proximity to Discovery Award for Knowledge Exchange) to test a large panel of our viral antibodies in immunofluorescence applications. This...

Why are ticks such good vectors of pathogens?

In this blog, Professor Patricia Nuttall discusses what makes ticks such effective vectors of pathogens and how we might prevent the spread of tick-borne diseases. About Patrica Nuttall Pat Nuttall is Emeritus Professor of Arbovirology in the Department of Zoology,...

Dengue in 2019

What's going on with dengue? Dengue virus (DENV) has been in the news a lot recently. The number of reported cases continues to climb year-on-year and 2019 has been especially bad. Rio de Janeiro has seen a 45% increase in dengue cases in the first two months of 2019...

Zika Prevalence in Suriname – an insight into assay cross-reactivity

A recent study published by Langerak et al tested for the seroprevalence of Zika virus in Suriname populations and evaluated the comparative effectiveness of using a commercial ELISA and a standard Virus Neutralisation Assay. Here we discuss the study, its results,...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

1 + 10 =

Live Customer Feedback